---
title: "Trending | RXRX Plummets 6% on Tuesday, Some Put options Surges 55%"
description: "On October 28, Eastern Time, Recursion Pharmaceuticals options saw a total of 135193 contracts traded, with calls accounting for 92% and puts making up 7%."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263209741.md"
published_at: "2025-10-29T04:28:45.000Z"
---

# Trending | RXRX Plummets 6% on Tuesday, Some Put options Surges 55%

> On October 28, Eastern Time, Recursion Pharmaceuticals options saw a total of 135193 contracts traded, with calls accounting for 92% and puts making up 7%.

On October 28, Eastern Time, Recursion Pharmaceuticals options saw a total of 135193 contracts traded, with calls accounting for 92% and puts making up 7%.

Recursion Pharmaceuticals has 482638 contracts outstanding, with calls accounting for 79% and puts making up 20%.

The top volume gainer was the 6.5 dollars Call option expiring on October 31, 2025, with 3212 contracts traded.

On the news front, Based on recent key news:

1\. Oct 28, Recursion Pharmaceuticals announced its upcoming Q3 financial results release on Nov 5, which may have influenced investor sentiment, leading to a stock price drop. The announcement was made via GlobeNewswire.

2\. Oct 27, MarketBeat reported that Recursion Pharmaceuticals was not among the top stocks recommended by analysts, which may have contributed to the negative sentiment and stock decline.

3\. Oct 26, Analysts maintained a Hold rating for Recursion Pharmaceuticals, suggesting limited upside potential compared to other stocks, impacting investor decisions.

Please note: The chart below does not include options expiring within five days.

![image](https://assets.lbctrl.com/h5hub/optrank/images/2025-10-29/ST_US_RXRX_en.png)

### Related Stocks

- [RXRX.US - Recursion Pharmaceuticals](https://longbridge.com/en/quote/RXRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades | Recursion Pharmaceuticals (RXRX) released new clinical data from the TUPELO trial for REC-4881, sparking interest due to | [Link](https://longbridge.com/en/news/270317663.md) |
| Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages | Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has received a consensus rating of "Hold" from six analysts. One analyst r | [Link](https://longbridge.com/en/news/272181644.md) |
| The Rise of Short-Dated Options | The Rise of Short-Dated Options | [Link](https://longbridge.com/en/news/275494337.md) |
| What Hundreds of Trades Reveal About Consistency in Weekly Option Income | What Hundreds of Trades Reveal About Consistency in Weekly Option Income | [Link](https://longbridge.com/en/news/275208634.md) |
| Intuit Options Activity Signals Potential Bullish Reversal | Intuit Options Activity Signals Potential Bullish Reversal | [Link](https://longbridge.com/en/news/275935163.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.